Abstract: The disclosure provides, inter alia, methods and reagents for use in measuring the attachment of ubiquitin and ubiquitin-like proteins to a target protein, particularly an E3 protein.

Abstract: Disclosed are methods and compositions for the identification of inhibitors of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.

Abstract: The application discloses compounds that inhibit ubiquitin ligase activity. The application further discloses antiviral compounds, anticancer compounds, and compounds useful for the treatment of neurological disorders.

Abstract: The disclosure provides, inter alia, methods and reagents for use in measuring the attachment of ubiquitin and ubiquitin-like proteins to a target protein, particularly an E3 protein.

Abstract: The application provides novel complexes of POSH polypeptides and POSH asoociated kinases. The application also provides methods and compositions for treating a POSH-associated diseases such as viral disorders and cancer.

Abstract: The application provides novel complexes of POSH polypeptides and POSH-associated proteins. The application also provides methods and compositions for treating POSH-associated diseases such as neurological disorders.

Abstract: The application relates to inhibitors of POSH-associated E2 enzymes, such as the UBC13/UEV1 complex. Methods of using such RNAi inhibitors for treating viral disorders, such as, for example, HIV infection, are also described.

Abstract: The application provides novel complexes of Cbl-b polypeptides and Cbl-b-associated proteins. The application also provides methods and compositions for treating Cbl-b-associated diseases such as viral disorders.

Abstract: The application discloses compounds that inhibit ubiquitin ligase activity. The application further discloses antiviral compounds, anticancer compounds, and compounds useful for the treatment of neurological disorders.

Abstract: The application discloses methods and compositions related to the modulation of trans-Golgi network-associated processes, including methods and compositions for the modulation of trans-Golgi network-associated proteins and methods for the treatment of disorders associated with trans-Golgi network processes.

Abstract: The application provides novel complexes of POSH polypeptides and POSH-associated proteins. The application also provides methods and compositions for treating POSH-associated diseases such as viral disorders, cancer, and neurological disorders.

Abstract: The application relates to methods of inhibiting a Nef-mediated process in a cell infected with HIV. The application also provides methods and compositions for treating POSH-associated and HERPUD1-associated diseases such as viral disorders.

Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.

Abstract: This application describes a family of nucleic acid sequences and proteins encoded thereby that play a role in viral maturation: the Alternate Viral Maturation Scaffolding Protein, or the AVMSP family of proteins.

Abstract: This invention relates to methods and reagents for selectively labeling membrane surface proteins using a labeling agent. The label may be used to isolate preparations of membrane surface proteins. Preparations of membrane surface proteins may be analysed by a variety of high-throughput techniques to allow rapid profiling of membrane surface protein composition.

Abstract: The disclosure provides, among other things, methods and compositions for treating HCAP associated diseases, such as malignant and benign cell hyperproliferative diseases. Preferred diseases include EGFR associated diseases, including cancers, e.g., breast cancer.

Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.

Abstract: This application provides methods for identifying and validating potential drug targets. In one aspect, the application provides a systematic method of creating a database of related protein or nucleic acid sequences with annotations of the potential disease associations of the sequences; and a method for testing the potential disease associations by means of a biological assay and validating the disease association by either decreasing expression of the sequence of interest or increasing expression of the sequence of interest.

Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.

Abstract: Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a families of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme.